Compare MDGL & ADT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | ADT |
|---|---|---|
| Founded | 2011 | 1874 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 5.4B |
| IPO Year | 2005 | 2017 |
| Metric | MDGL | ADT |
|---|---|---|
| Price | $436.69 | $6.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $674.45 | $8.38 |
| AVG Volume (30 Days) | 321.8K | ★ 9.2M |
| Earning Date | 05-19-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | ★ 41.32 | 29.63 |
| EPS | N/A | ★ N/A |
| Revenue | $180,133,000.00 | ★ $5,128,607,000.00 |
| Revenue This Year | $58.70 | $5.00 |
| Revenue Next Year | $46.88 | $3.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 4.70 |
| 52 Week Low | $265.00 | $6.27 |
| 52 Week High | $615.00 | $8.94 |
| Indicator | MDGL | ADT |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 35.47 |
| Support Level | $416.43 | $6.27 |
| Resistance Level | $446.51 | $8.30 |
| Average True Range (ATR) | 15.45 | 0.23 |
| MACD | 3.53 | -0.02 |
| Stochastic Oscillator | 62.03 | 20.85 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.